An Open-Label Dose-Escalation Study to Evaluate XmAb24306 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors

  • Cancer
  • Solid Tumors
Please note that the recruitment status of the trial at your site may differ from the overall study status because some study sites may recruit earlier than others.
Trial Status:

Active, not recruiting

This trial runs in
Countries
  • Australia
  • Belgium
  • Brazil
  • Canada
  • Italy
  • Netherlands
  • South Korea
  • Spain
  • United States
Trial Identifier:

NCT04250155 GO41596

      Show trial locations

      The source of the below information is public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc.. It has been summarised and edited into simpler language. For more information about this clinical trial see the For Expert tab on the specific ForPatients page or follow these links to https://clinicaltrials.gov and/or https://euclinicaltrials.eu and/or https://www.isrctn.com.

      The below information is taken directly from public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc., and has not been edited.

      Results Disclaimer

      Trial Summary

      This study will evaluate the safety, tolerability, pharmacokinetics, and activity of XmAb24306 alone or in combination with a checkpoint inhibitor treatment in participants with locally advanced or metastatic solid tumors.

      Genentech, Inc. Sponsor
      Phase 1 Phase
      NCT04250155, GO41596 Trial Identifier
      XmAb24306, Atezolizumab, XmAb24306 Treatments
      Solid Tumors Condition
      Official Title

      A Phase Ia/Ib, Open-Label, Multicenter, Global, Dose-Escalation Study to Evaluate the Safety and Pharmacokinetics of XmAb24306 as a Single Agent and in Combination With Atezolizumab in Patients With Locally Advanced or Metastatic Solid Tumors

      Eligibility Criteria

      All Gender
      ≥18 Years Age
      No Healthy Volunteers
      Inclusion Criteria

      Key General Inclusion Criteria

      • Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1
      • Life expectancy >/= 12 weeks
      • Adequate hematologic and end-organ function
      • For participants receiving therapeutic anticoagulation: stable anticoagulant regimen
      • Negative serum pregnancy test for women of childbearing potential
      • Histologically confirmed locally advanced, recurrent, or metastatic incurable solid tumor malignancy
      • Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1
      • Availability of representative tumor specimens

       

      Exclusion Criteria

      Key General Exclusion Criteria

      • Pregnant or breastfeeding, or intending to become pregnant during the study
      • Significant cardiovascular disease
      • Current treatment with medications that prolong the QT interval
      • Known clinically significant liver disease
      • Poorly controlled Type 2 diabetes mellitus
      • Symptomatic, untreated, or actively progressing CNS metastases
      • History of leptomeningeal disease
      • History of malignancy other than disease under study within 3 years prior to screening
      • Active or history of autoimmune disease or immune deficiency
      • Active tuberculosis, hepatitis B, hepatitis C, or known/suspected Epstein Barr virus infection
      • Positive for HIV infection
      • Prior allogeneic stem cell or solid organ transplantation

      For the latest version of this information please go to www.forpatients.roche.com

       

      Related Trials

      Use our search to find other trials on ForPatients in related disease areas.

      Solid Tumors

      Clinical Research Explained

      Information about what clinical trials and observational studies are. Understand why you might want to take part in clinical research and why diversity in clinical research is important.

      Find out now